Richard Tobin - Dissemin

All papers authored by Richard Tobin

This paper is made freely available by the publisher.

2024 Nabanita Mukherjee, Elizabeth Katsnelson, Tonya M. Brunetti, Kylie Michel, Kasey L. Couts, Karoline A. Lambert, William A. Robinson, Martin D. McCarter, David A. Norris, Richard P. Tobin

, Yiqun G. Shellman

MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade

Download from doi.org

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

J. S. W. Borgers

, A. W. van Schijndel

, J. V. van Thienen, S. Klobuch, T. T. P. Seijkens, R. P. Tobin

, L. van Heerebeek, A. Driessen-Waaijer, M. W. Rohaan, J. B. A. G. Haanen

Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned

Upload

This paper was not found in any repository, but could be made available legally by the author.

2023 William H. Palmer

, Laura Ann Leaton

, Ana Campos Codo

, Bergren Crute

, James Roest

, Shiying Zhu, Jan Petersen

, Richard P. Tobin

, Patrick S. Hume

, Matthew Stone, Adrie van Bokhoven

, Mark E. Gerich

, Martin D. McCarter

, Yuwen Zhu

, William J. Janssen

and 7 other authors

Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells

Upload

Richard P. Tobin

, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S. W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao

, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland and 2 other authors

Supplementary table 2 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Upload

Richard P. Tobin

, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S. W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao

, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland and 2 other authors

Supplementary table 3 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Upload

Richard P. Tobin

, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S. W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao

, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland and 2 other authors

Supplementary table 4 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Upload

Richard P. Tobin

, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S. W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao

, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland and 2 other authors

Data from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Upload

Richard P. Tobin

, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S. W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao

, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland and 2 other authors

Supplementary Figure S1 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Upload

Richard P. Tobin

, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S. W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao

, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland and 2 other authors

Supplementary table 1 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Upload

Richard P. Tobin

, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S. W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao

, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland and 2 other authors

Supplementary Figure S2 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Upload

Richard P. Tobin

, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S. W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao

, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland and 2 other authors

Supplementary Table 5 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Upload

2022 Richard P. Tobin

, Dasha T. Cogswell

, Victoria M. Cates

, Dana M. Davis

, Jessica S. W. Borgers

, Robert J. Van Gulick

, Elizabeth Katsnelson

, Kasey L. Couts

, Kimberly R. Jordan

, Dexiang Gao

, Eduardo Davila

, Theresa M. Medina

, Karl D. Lewis

, Rene Gonzalez

, Ross W. McFarland

and 2 other authors

Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Richard Tobin